Evidence map›Paper›PMID 30871403›Full record

ArticleEpigenetics2019

DNA methylation changes associated with Parkinson's disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood.

Adrienne Henderson-Smith, Kathleen M Fisch, Jianping Hua, Ganqiang Liu, Eugenia Ricciardelli, Kristen Jepsen, Mathew Huentelman, Gabriel Stalberg, Steven D Edland, Clemens R Scherzer and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. DNA Methylation in Long-Term Memory.Physiology (Bethesda, Md.) · 2025
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Novel therapeutic approaches to target neurodegeneration.British journal of pharmacology · 2023
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Adrienne Henderson-Smitha Biodesign Institute , Arizona State University , Tempe , AZ , USA.
Kathleen M Fischc Center for Computational Biology & Bioinformatics, Department of Medicine , University of California San Diego , La Jolla , CA , USA.
Jianping Huad Center for Bioinformatics and Genomics Systems Engineering, Texas A&M Engineering Experiment Station , Texas A&M University , College Station , TX , USA.
Ganqiang Liue Advanced Center for Parkinson's Disease Research and Precision Neurology Program, Harvard Medical School , Brigham & Women's Hospital , Boston , MA , USA.
Eugenia Ricciardellif Genomics Center, Institute for Genomics Medicine , University of California San Diego , La Jolla , CA , USA.
Kristen Jepsenf Genomics Center, Institute for Genomics Medicine , University of California San Diego , La Jolla , CA , USA.
Mathew Huentelmanb Neurogenomics Division , Translational Genomics Research Institute , Phoenix , AZ , USA.
Gabriel Stalberge Advanced Center for Parkinson's Disease Research and Precision Neurology Program, Harvard Medical School , Brigham & Women's Hospital , Boston , MA , USA.
Steven D Edlandh Department of Neurosciences , University of California San Diego , La Jolla , CA , USA.
Clemens R Scherzere Advanced Center for Parkinson's Disease Research and Precision Neurology Program, Harvard Medical School , Brigham & Women's Hospital , Boston , MA , USA.
Travis Dunckleya Biodesign Institute , Arizona State University , Tempe , AZ , USA.
Paula Desplatsh Department of Neurosciences , University of California San Diego , La Jolla , CA , USA.
University of California, San Diego · USBrigham and Women's Hospital · USTranslational Genomics Research Institute · USArizona State University · USHarvard University · USTexas A&M University · US

Funding

GBA pathway markers for Lewy body dementiasU01NS100603 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2016 to 2020
$2.9M
Biomarkers for early intervention in Parkinson diseaseU01NS082157 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2012 to 2016
$2.5M
Parkinson Disease: Predicting the FutureU01NS095736 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2016 to 2018
$2.1M
NINDS NIH HHS U01 NS082157NINDS NIH HHS U01 NS095736NINDS NIH HHS U01 NS100603
6 · The paper itself

Abstract

Parkinson's Disease (PD) is a common neurodegenerative disorder currently diagnosed based on the presentation of characteristic movement symptoms. Unfortunately, patients exhibiting these symptoms have already undergone significant dopaminergic neuronal loss. Earlier diagnosis, aided by molecular biomarkers specific to PD, would improve overall patient care. Epigenetic mechanisms, which are modified by both environment and disease pathophysiology, are emerging as important components of neurodegeneration. Alterations to the PD methylome have been reported in epigenome-wide association studies. However, the extent to which methylation changes correlate with disease progression has not yet been reported; nor the degree to which methylation is affected by PD medication. We performed a longitudinal genome-wide methylation study surveying ~850,000 CpG sites in whole blood from 189 well-characterized PD patients and 191 control individuals obtained at baseline and at a follow-up visit ~2 y later. We identified distinct patterns of methylation in PD cases versus controls. Importantly, we identified genomic sites where methylation changes longitudinally as the disease progresses. Moreover, we identified methylation changes associated with PD pathology through the analysis of PD cases that were not exposed to anti-parkinsonian therapy. In addition, we identified methylation sites modulated by exposure to dopamine replacement drugs. These results indicate that DNA methylation is dynamic in PD and changes over time during disease progression. To the best of our knowledge, this is the first longitudinal epigenome-wide methylation analysis for Parkinson's disease and reveals changes associated with disease progression and in response to dopaminergic medications in the blood methylome.

Indexed as

DNA MethylationAgedBiomarkersCpG IslandsDNAFemaleHumansMaleMiddle AgedParkinson DiseaseBiomarkersDNAbiomarkersblood epigenomedisease progressionDNA methylationdopamine replacement therapylongitudinalone-carbon metabolismParkinson’s disease

Identifiers

PMID30871403
PMCPMC6557551
OpenAlexW2921058608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.